Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function ...
Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP "top-up" reimbursement; On track ...
South Africa’s best source of news, opinion, and analysis from the business sector and political economy. Includes Business Day, Financial Mail, and Business Times. Markets. Indicators. JSE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback